Although there are many subtypes of B lymphomas, an intriguing common feature is that all types of B lymphomas require BCR signals to gain advantages in their tumorigenesis in vivo10,11 and the BTK inhibitor has demonstrated clinical benefit for several types of B cell lymphomas. The gene discussed is BCR; the disease is B-cell non-Hodgkin lymphoma.